JP2024511995A5 - - Google Patents
Info
- Publication number
- JP2024511995A5 JP2024511995A5 JP2023557284A JP2023557284A JP2024511995A5 JP 2024511995 A5 JP2024511995 A5 JP 2024511995A5 JP 2023557284 A JP2023557284 A JP 2023557284A JP 2023557284 A JP2023557284 A JP 2023557284A JP 2024511995 A5 JP2024511995 A5 JP 2024511995A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- treatment
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162691P | 2021-03-18 | 2021-03-18 | |
| US63/162,691 | 2021-03-18 | ||
| PCT/US2022/020878 WO2022198001A1 (en) | 2021-03-18 | 2022-03-18 | Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511995A JP2024511995A (ja) | 2024-03-18 |
| JP2024511995A5 true JP2024511995A5 (enExample) | 2025-06-23 |
Family
ID=83320877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557284A Pending JP2024511995A (ja) | 2021-03-18 | 2022-03-18 | がん治療における第一選択療法としてのｓＥｐｈＢ４－ＨＳＡ融合タンパク質の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240156908A1 (enExample) |
| EP (1) | EP4308149A4 (enExample) |
| JP (1) | JP2024511995A (enExample) |
| KR (1) | KR20230173108A (enExample) |
| CN (1) | CN117120074A (enExample) |
| AU (1) | AU2022239581A1 (enExample) |
| CA (1) | CA3211742A1 (enExample) |
| WO (1) | WO2022198001A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274305B1 (en) * | 1996-12-19 | 2001-08-14 | Tufts University | Inhibiting proliferation of cancer cells |
| JP6877419B2 (ja) * | 2015-10-27 | 2021-05-26 | ザ ユニバーシティー オブ クイーンズランド | 治療の方法およびそのために有用な剤 |
| CA3139416A1 (en) * | 2019-02-13 | 2020-08-20 | Vasgene Therapeutics Inc | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
| AU2020241963A1 (en) * | 2019-03-17 | 2021-11-04 | Vasgene Therapeutics Inc | Treatment of cancers using sEphB4-HSA fusion proteins |
-
2022
- 2022-03-18 EP EP22772256.8A patent/EP4308149A4/en active Pending
- 2022-03-18 JP JP2023557284A patent/JP2024511995A/ja active Pending
- 2022-03-18 WO PCT/US2022/020878 patent/WO2022198001A1/en not_active Ceased
- 2022-03-18 AU AU2022239581A patent/AU2022239581A1/en active Pending
- 2022-03-18 CN CN202280022432.5A patent/CN117120074A/zh active Pending
- 2022-03-18 US US18/282,538 patent/US20240156908A1/en active Pending
- 2022-03-18 CA CA3211742A patent/CA3211742A1/en active Pending
- 2022-03-18 KR KR1020237035777A patent/KR20230173108A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mosesson et al. | Oncogenic growth factor receptors: implications for signal transduction therapy | |
| Troiani et al. | Targeting EGFR in pancreatic cancer treatment | |
| JP2022525223A5 (enExample) | ||
| Caponigro et al. | Treatment approaches to nasopharyngeal carcinoma: a review | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| JP2017537090A5 (enExample) | ||
| JP2012102109A5 (enExample) | ||
| JP2022520596A5 (enExample) | ||
| JP2017514847A (ja) | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン | |
| TW202330589A (zh) | 治療 | |
| Gampenrieder et al. | Treatment landscape for patients with HER2-positive metastatic breast cancer: a review on emerging treatment options | |
| Tan et al. | Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities | |
| Jacob et al. | Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck | |
| Qureshi et al. | Immunotherapy approaches beyond PD-1 inhibition: the future of cellular therapy for head and neck squamous cell carcinoma | |
| JP2024511995A5 (enExample) | ||
| TW202328212A (zh) | Ｍａｇｅ—ａ４陽性癌症之治療 | |
| Modi et al. | An update on epidermal growth factor receptor inhibitors | |
| He et al. | Evolving landscape of HER2-targeted therapies for gastric cancer patients | |
| Clark et al. | Recent progress in systemic treatment for lung cancer | |
| Gerber et al. | Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC | |
| KR20160007640A (ko) | Muc-1 리포펩티드를 이용한 백신접종에 의한 폐암의 치료 방법 | |
| JP2023537115A5 (enExample) | ||
| Puttagunta et al. | Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck | |
| JP2024534935A5 (enExample) | ||
| Schwartz et al. | 4-1BB Antibodies in Oncology Clinical Trials: A Review |